🗞️ Why in News India launched a nationwide free HPV vaccination drive on February 28, 2026, targeting 14-year-old girls. India records over 1.2 lakh new cervical cancer cases and approximately 80,000 deaths annually, the highest absolute burden globally.
The Editorial Argument
The Hindu editorial argues that while the national HPV vaccination campaign is a landmark public health intervention, vaccination alone is insufficient. India must simultaneously scale up cervical cancer screening (currently covering less than 2% of eligible women), address rural-urban disparities, tackle vaccine hesitancy, and build treatment infrastructure to meet the WHO 90-70-90 targets by 2030.
India’s Cervical Cancer Burden
| Metric | Data |
|---|---|
| New cases annually | ~1.2 lakh (1,23,907, Globocan 2022) |
| Annual deaths | ~79,000 |
| India’s share of global cases | ~23% |
| Leading cause of cancer death among women (India) | 2nd (after breast cancer) |
| Screening coverage | <2% of eligible women |
| HPV prevalence (high-risk types) | ~5-8% among women aged 15-59 |
HPV Vaccination: The National Programme
| Feature | Detail |
|---|---|
| Launched | February 28, 2026 |
| Target group | Girls aged 14 years |
| Vaccine | Made-in-India quadrivalent HPV vaccine (Cervavac by Serum Institute of India) |
| Dosage | Single dose (following WHO’s 2022 recommendation for single-dose efficacy) |
| Delivery | Through schools and Anganwadi centres via Universal Immunisation Programme (UIP) |
| Cost | Free under government programme; market price ~Rs 2,000-4,000 per dose |
Cervavac: India’s Indigenous HPV Vaccine
Developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT):
- Type: Quadrivalent (targets HPV types 6, 11, 16, 18)
- HPV 16 and 18: Cause ~70% of cervical cancers globally
- HPV 6 and 11: Cause ~90% of genital warts
- Approval: DCGI approval received July 2022
- Significance: India becomes self-sufficient in HPV vaccine production, reducing dependence on Gardasil (Merck) and Cervarix (GSK)
The Screening Gap
Vaccination protects future generations, but the ~300 million women currently aged 30-65 remain unprotected, they need screening. India’s screening infrastructure is severely inadequate:
| Screening Method | Availability | WHO Recommendation |
|---|---|---|
| Pap smear | Limited to urban hospitals; requires trained cytologists | Every 3 years (age 21-65) |
| VIA (Visual Inspection with Acetic Acid) | Available at PHCs; lower sensitivity | Every 5 years |
| HPV DNA test | Most accurate; available only at tertiary centres | Preferred method; every 5-10 years |
The editorial recommends HPV DNA testing as the primary screening tool, it can be self-collected, processed in batched labs, and has the highest sensitivity (~95%) for detecting high-risk HPV infections before they progress to cancer.
WHO 90-70-90 Targets (by 2030)
The WHO Global Strategy to Eliminate Cervical Cancer sets three targets:
- 90% of girls fully vaccinated with HPV vaccine by age 15
- 70% of women screened with a high-performance test by age 35 and again by 45
- 90% of women with cervical disease receiving treatment
India’s current status against these targets:
- Vaccination: Campaign just launched (February 2026), coverage <5%
- Screening: <2% coverage (target: 70%)
- Treatment: ~60-70% of diagnosed cases receive treatment (target: 90%)
Vaccine Hesitancy
The editorial notes that vaccine hesitancy, fuelled by misinformation about HPV vaccine causing infertility, remains a significant barrier. The 2009 PATH-ICMR HPV vaccine trial controversy (deaths during trial in Andhra Pradesh and Gujarat led to a Parliamentary Committee inquiry) continues to cast a shadow over HPV vaccination acceptance in India.
UPSC Relevance
Prelims: HPV types 16/18, Cervavac manufacturer (SII), WHO 90-70-90 targets, cervical cancer statistics, UIP
Mains GS-2: Health policy, vaccination programmes, screening infrastructure, rural-urban health disparities, women’s health
Mains GS-3: Science & Technology, indigenous vaccine development, public health innovation
📌 Facts Corner: Knowledgepedia
Cervical Cancer in India:
- New cases: ~1.2 lakh/year; deaths: ~79,000/year
- India’s share of global cases: ~23%
- Screening coverage: <2% of eligible women
- Cause: HPV (Human Papillomavirus), types 16 and 18 cause ~70% of cases
HPV Vaccination (India):
- National programme launched: February 28, 2026
- Vaccine: Cervavac (Serum Institute of India, quadrivalent)
- Target: Girls aged 14; single dose; via UIP
- HPV types covered: 6, 11, 16, 18
- WHO single-dose recommendation: April 2022
WHO 90-70-90 Targets:
- 90% vaccination by age 15
- 70% screening by age 35 and 45
- 90% treatment for cervical disease
- Timeline: By 2030
Other Relevant Facts:
- SII: World’s largest vaccine manufacturer by volume (Pune)
- DBT: Department of Biotechnology (co-developed Cervavac)
- PATH-ICMR trial controversy: 2009; led to Parliamentary inquiry
- VIA: Visual Inspection with Acetic Acid, low-cost screening at PHCs
- HPV DNA test: Gold standard; ~95% sensitivity; self-collection possible
Interview Angle
"India accounts for 23% of global cervical cancer cases despite the disease being almost entirely preventable through HPV vaccination and screening. What systemic failures explain this paradox?"
Cite this page: Ramping Up the Fight Against Cervical Cancer, Beyond Vaccination — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
